75 related articles for article (PubMed ID: 24011995)
1. Infliximab for the treatment of refractory noninfectious Uveitis: a study of 88 patients with long-term follow-up.
Kruh JN; Yang P; Suelves AM; Foster CS
Ophthalmology; 2014 Jan; 121(1):358-364. PubMed ID: 24011995
[TBL] [Abstract][Full Text] [Related]
2. Effects of non-medical infliximab biosimilar switching in ocular inflammatory diseases: A case series from a tertiary care center.
Dolinko AH; Morvey DE; Apoorva S; Chikovsky M; Anesi SD; Foster CS
Eur J Ophthalmol; 2024 May; 34(3):774-780. PubMed ID: 37671431
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes of noninfectious uveitis treated with systemic immunomodulatory therapy: a retrospective case series.
Felfeli T; Balas M; Tai F; Eshtiaghi A; Rhee J; Kaplan AJ; Christakis PG; Mandelcorn ED; Bakshi NK; Rubin LA; Derzko-Dzulynsky LA
Can J Ophthalmol; 2024 Jun; ():. PubMed ID: 38889882
[TBL] [Abstract][Full Text] [Related]
4. Outcome Preferences in Patients With Noninfectious Uveitis: Results of a Best-Worst Scaling Study.
Yu T; Holbrook JT; Thorne JE; Flynn TN; Van Natta ML; Puhan MA
Invest Ophthalmol Vis Sci; 2015 Oct; 56(11):6864-72. PubMed ID: 26501236
[TBL] [Abstract][Full Text] [Related]
5. Adalimumab in Patients with Active Noninfectious Uveitis.
Jaffe GJ; Dick AD; Brézin AP; Nguyen QD; Thorne JE; Kestelyn P; Barisani-Asenbauer T; Franco P; Heiligenhaus A; Scales D; Chu DS; Camez A; Kwatra NV; Song AP; Kron M; Tari S; Suhler EB
N Engl J Med; 2016 Sep; 375(10):932-43. PubMed ID: 27602665
[TBL] [Abstract][Full Text] [Related]
6. Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network.
Vallet H; Seve P; Biard L; Baptiste Fraison J; Bielefeld P; Perard L; Bienvenu B; Abad S; Rigolet A; Deroux A; Sene D; Perlat A; Marie I; Feurer E; Hachulla E; Fain O; Clavel G; Riviere S; Bouche PA; Gueudry J; Pugnet G; Le Hoang P; Resche Rigon M; Cacoub P; Bodaghi B; Saadoun D;
Arthritis Rheumatol; 2016 Jun; 68(6):1522-30. PubMed ID: 27015607
[TBL] [Abstract][Full Text] [Related]
7. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
[TBL] [Abstract][Full Text] [Related]
8. Advancements in the management of uveitis.
Schwartzman S
Best Pract Res Clin Rheumatol; 2016 Apr; 30(2):304-315. PubMed ID: 27886802
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal Sirolimus for Noninfectious Uveitis: A Phase III Sirolimus Study Assessing Double-masKed Uveitis TReAtment (SAKURA).
Nguyen QD; Merrill PT; Clark WL; Banker AS; Fardeau C; Franco P; LeHoang P; Ohno S; Rathinam SR; Thurau S; Abraham A; Wilson L; Yang Y; Shams N;
Ophthalmology; 2016 Nov; 123(11):2413-2423. PubMed ID: 27692526
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor necrosis factor-α therapy in uveitis.
Cordero-Coma M; Sobrin L
Surv Ophthalmol; 2015; 60(6):575-89. PubMed ID: 26164735
[TBL] [Abstract][Full Text] [Related]
11. Success of Weekly Adalimumab in Refractory Ocular Inflammatory Disease.
Lee J; Koreishi AF; Zumpf KB; Minkus CL; Goldstein DA
Ophthalmology; 2020 Oct; 127(10):1431-1433. PubMed ID: 32423769
[No Abstract] [Full Text] [Related]
12. Update in treatment of uveitic macular edema.
Koronis S; Stavrakas P; Balidis M; Kozeis N; Tranos PG
Drug Des Devel Ther; 2019; 13():667-680. PubMed ID: 30858697
[TBL] [Abstract][Full Text] [Related]
13. Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics.
Thomas AS
Curr Opin Ophthalmol; 2019 May; 30(3):138-150. PubMed ID: 30844945
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of intravitreal anti-tumour necrosis factor drugs in adults with non-infectious uveitis - a systematic review.
Leal I; Rodrigues FB; Sousa DC; Romão VC; Duarte GS; Carreño E; Dick AD; Marques-Neves C; Costa J; Fonseca JE
Acta Ophthalmol; 2018 Sep; 96(6):e665-e675. PubMed ID: 29577629
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of infliximab, adalimumab and golimumab for non-infectious refractory uveitis in adults.
Borrás-Blasco J; Casterá DE; Cortes X; Abad FJ; Rosique-Robles JD; Mallench LG
Int J Clin Pharmacol Ther; 2015 May; 53(5):377-90. PubMed ID: 25345430
[TBL] [Abstract][Full Text] [Related]
16. Inflammatory cytokines as mediators of retinal endothelial barrier dysfunction in non-infectious uveitis.
Ferreira LB; Williams KA; Best G; Haydinger CD; Smith JR
Clin Transl Immunology; 2023; 12(12):e1479. PubMed ID: 38090668
[TBL] [Abstract][Full Text] [Related]
17. The incidence, presenting clinical findings and treatment patterns of Birdshot Retinochoroiditis in a high-prevalence region: findings from Northern Ireland, England and Wales.
Khalil R; Petrushkin H; Rees A; Westcott M
Eye (Lond); 2023 Sep; 37(13):2817-2825. PubMed ID: 36765269
[TBL] [Abstract][Full Text] [Related]
18. Pediatric uveitis: Role of the pediatrician.
Shivpuri A; Turtsevich I; Solebo AL; Compeyrot-Lacassagne S
Front Pediatr; 2022; 10():874711. PubMed ID: 35979409
[TBL] [Abstract][Full Text] [Related]
19. A Review of Systemic Biologics and Local Immunosuppressive Medications in Uveitis.
S Mehta N; Emami-Naeini P
J Ophthalmic Vis Res; 2022; 17(2):276-289. PubMed ID: 35765634
[TBL] [Abstract][Full Text] [Related]
20. The Efficacy and Safety of Infliximab in Refractory Noninfectious Uveitis: A Meta-Analysis of Observational Studies.
Xiong A; Liu D; Chen H; Yang G; Xiong C; Shuai Y; He L; Guo Z; Zhang L; Yang Y; Cui B; Shuai S
Front Pharmacol; 2021; 12():620340. PubMed ID: 34603013
[No Abstract] [Full Text] [Related]
[Next] [New Search]
